10x Genomics (TXG) Cash & Equivalents (2018 - 2026)

10x Genomics (TXG) has 9 years of Cash & Equivalents data on file, last reported at $490.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 30.03% year-over-year to $490.3 million; the trailing twelve-month figure through Mar 2026 stood at $490.3 million (up 30.03% YoY), and the FY2025 full-year result was $474.0 million, up 37.75% from the prior year.
• Cash & Equivalents improved to $490.3 million in Q1 2026, from $474.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $490.3 million in Q1 2026 to a low of $219.7 million in Q4 2022.
• A 5-year average of $354.0 million and a median of $355.8 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 62.59% in 2022 and soared 63.5% in 2023, its largest moves.
• Tracing TXG's Cash & Equivalents over 5 years: stood at $219.7 million in 2022, then surged by 63.5% to $359.3 million in 2023, then declined by 4.24% to $344.1 million in 2024, then soared by 37.75% to $474.0 million in 2025, then advanced by 3.44% to $490.3 million in 2026.
• Business Quant data shows TXG's Cash & Equivalents at $490.3 million in Q1 2026, $474.0 million in Q4 2025, and $432.5 million in Q3 2025.